Apixaban in Obese Patients

Please use landscape view or desktop screen to view the content.

Reduction of Risk of Stroke and Systemic Embolism in Patients With NVAF

The recommended dose of ELIQUIS^® for most patients is 5 mg taken orally twice daily.

The recommended dose of ELIQUIS^® is 2.5 mg twice daily in patients with at least 2 of the following
characteristics:

Age ≥80 years
Body weight ≤60 kg
Serum creatinine ≥1.5 mg/dL

Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery

The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery.

In patients undergoing hip replacement surgery, the recommended duration of treatment is 35 days
In patients undergoing knee replacement surgery, the recommended duration of treatment is 12 days

Treatment of DVT and PE

The recommended dose of ELIQUIS is 10 mg taken orally twice daily for the first 7 days of therapy. After
7 days, the recommended dose is 5 mg taken orally twice daily.

*ESRD subjects treated with intermittent hemodialysis; reported PK findings are following single dose of apixaban post hemodialysis.
^†Results reflect CrCl of 15 mL/min based on regression analysis.
^‡Dashed vertical lines illustrate PK changes that were used to inform dosing recommendations.
^§No dose adjustment is recommended for nonvalvular atrial fibrillation patients unless at least 2 of the following patient characteristics (age ≥80 years, body weight ≤60 kg,
or serum creatinine ≥1.5 mg/dL) are present.

AUC, area under the curve; CI, confidence interval; C_max, maximum plasma concentration; CrCl, creatinine clearance; DVT, deep vein thrombosis; ESRD, end-stage renal disease;
NVAF, nonvalvular atrial fibrillation; PE, pulmonary embolism; PK, pharmacokinetics.

Dosing Recommendations and the Effect of Specific Populations on the PK of Apixaban1,2

Dosing Recommendations and the Effect of Specific Populations on the PK of Apixaban^1,2